thalidomide has been researched along with Benign Neoplasms in 222 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis." | 9.24 | Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). ( Cather, JC; Chen, R; Crowley, J; Day, RM; Ferrándiz, C; Goncalves, J; Joly, P; Papp, KA; Peris, K; Shah, K; Thaçi, D, 2017) |
| "Purpose We examined the efficacy and safety of thalidomide (THD) for the prevention of delayed nausea and vomiting in patients who received highly emetogenic chemotherapy (HEC)." | 9.24 | Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study). ( An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z, 2017) |
| "To explore the efficacy and safety of thalidomide for the treatment of delayed vomiting, induced by chemotherapy in cancer patients." | 9.22 | Thalidomide for Control Delayed Vomiting in Cancer Patients Receiving Chemotherapy. ( Du, X; Han, Z; Jiang, G; Sun, X, 2016) |
| "We completed a two-stage Phase II dose titration study of thalidomide, the primary purpose of which was to assess appetite response to thalidomide in cancer-associated anorexia." | 9.16 | A Phase II dose titration study of thalidomide for cancer-associated anorexia. ( Bicanovsky, L; Davis, M; Lagman, R; Lasheen, W; Mahmoud, F; Walsh, D, 2012) |
| "To determine the effects of thalidomide and placebo on anorexia-cachexia and its related symptoms, body composition, resting metabolic rate, and serum cytokines and their receptors in patients with advanced cancer." | 9.16 | The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. ( Allo, J; Bruera, E; Cohen, EN; Del Fabbro, E; Palmer, JL; Reuben, JM; Tin, S; Willey, JS; Yennurajalingam, S, 2012) |
| "This review aimed to (1) evaluate the effectiveness of thalidomide, and (2) identify and assess adverse effects from thalidomide for cancer cachexia." | 8.88 | Thalidomide for managing cancer cachexia. ( Cantwell, M; Cardwell, CR; Donnelly, M; Mills, M; Murray, LJ; Reid, J, 2012) |
| "Deep venous thrombosis (DVT) is a common complication of thalidomide treatment." | 7.73 | Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. ( Baumann, MA; Ikhlaque, N; Kathula, S; Seshadri, V, 2006) |
| "Thalidomide is being increasingly used after stem cell transplantation as immunosuppression for patients with chronic graft-versus-host disease, as well as for antiangiogenesis effects in patients with multiple myeloma, brain tumors, leukemia, or other malignancies." | 7.71 | Thalidomide in chronic graft-versus-host disease after stem cell transplantation: effects on quality of life. ( Mehta, P; Miller, S; Rodrigue, J; Sharda, S, 2002) |
| "The management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge in clinical practice." | 6.77 | Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. ( Cao, YZ; Li, X; Peng, LM; Shi, YM; Wen, HS; Yang, F; Zhang, CC, 2012) |
| " In all, 87% of adverse effects were classified as grade 1 or grade 2 according to Common Toxicity Criteria and there were no serious adverse events attributable to CC-5013 treatment." | 6.71 | Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. ( Bartlett, JB; Clarke, IA; Dalgleish, AG; Dredge, K; Kristeleit, H; Michael, A; Muller, GW; Nicholson, S; Pandha, H; Polychronis, A; Stirling, DI; Zeldis, J, 2004) |
| "Thalidomide was developed in the 1950s as a sedative having only a low toxicity." | 6.42 | [New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004) |
| "The risk of developing a malignancy during treatment is an important consideration, and many studies have been conducted to determine the magnitude of this risk." | 5.51 | Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review ( Casseres, RG; Dumont, N; Gottlieb, AB; Her, MJ; Kahn, JS; Rosmarin, D, 2019) |
| "Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis." | 5.24 | Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). ( Cather, JC; Chen, R; Crowley, J; Day, RM; Ferrándiz, C; Goncalves, J; Joly, P; Papp, KA; Peris, K; Shah, K; Thaçi, D, 2017) |
| "Purpose We examined the efficacy and safety of thalidomide (THD) for the prevention of delayed nausea and vomiting in patients who received highly emetogenic chemotherapy (HEC)." | 5.24 | Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study). ( An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z, 2017) |
| "Indoloquinoline (IQ) is an important class of naturally occurring antimalarial alkaloids, mainly represented by cryptolepine, isocryptolepine, and neocryptolepine." | 5.22 | Role of basic aminoalkyl chains in the lead optimization of Indoloquinoline alkaloids. ( Bharate, SB; Mudududdla, R; Nuthakki, VK, 2022) |
| "To explore the efficacy and safety of thalidomide for the treatment of delayed vomiting, induced by chemotherapy in cancer patients." | 5.22 | Thalidomide for Control Delayed Vomiting in Cancer Patients Receiving Chemotherapy. ( Du, X; Han, Z; Jiang, G; Sun, X, 2016) |
| "Data were obtained from a Phase II, randomized, double-blind Bayesian pick-the-winner trial of prednisone and pomalidomide in patients with MPN-associated myelofibrosis and anemia (red blood cell-transfusion dependence)." | 5.19 | Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. ( Cervantes, F; Gale, RP; Hudgens, S; Khan, ZM; Mesa, R; Passamonti, F; Rivera, C; Tefferi, A; Tencer, T; Verstovsek, S, 2014) |
| "We completed a two-stage Phase II dose titration study of thalidomide, the primary purpose of which was to assess appetite response to thalidomide in cancer-associated anorexia." | 5.16 | A Phase II dose titration study of thalidomide for cancer-associated anorexia. ( Bicanovsky, L; Davis, M; Lagman, R; Lasheen, W; Mahmoud, F; Walsh, D, 2012) |
| "To determine the effects of thalidomide and placebo on anorexia-cachexia and its related symptoms, body composition, resting metabolic rate, and serum cytokines and their receptors in patients with advanced cancer." | 5.16 | The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. ( Allo, J; Bruera, E; Cohen, EN; Del Fabbro, E; Palmer, JL; Reuben, JM; Tin, S; Willey, JS; Yennurajalingam, S, 2012) |
| "Three hundred thirty-two assessable patients with cancer-related anorexia/cachexia syndrome were randomly assigned to one of five treatment arms: arm 1, medroxyprogesterone (500 mg/day) or megestrol acetate (320 mg/day); arm 2, oral supplementation with eicosapentaenoic acid; arm 3, L-carnitine (4 g/day); arm 4, thalidomide (200 mg/day); and arm 5, a combination of the above." | 5.14 | Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. ( Contu, P; Dessì, M; Macciò, A; Madeddu, C; Mantovani, G; Massa, E; Panzone, F; Serpe, R, 2010) |
| "Three hundred and thirty-two assessable patients with cancer-related anorexia/cachexia syndrome (CACS) were randomly assigned to one of five arms of treatment: 1--medroxyprogesterone 500 mg/d or megestrol acetate 320 mg/d; 2--oral supplementation with eicosapentaenoic acid (EPA); 3--L-carnitine 4 g/d; 4--thalidomide 200 mg/d; 5--a combination of the above." | 5.14 | Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. ( Mantovani, G, 2010) |
| "Lenalidomide is an immunomodulatory drug (IMiD), which is well established and approved in the treatment of multiple myeloma (MM) and 5q-myelodysplastic syndrome (MDS)." | 4.90 | Lenalidomide. ( Kanz, L; Weisel, K, 2014) |
| " Central hypothyroidism is a well-recognized side effect of bexarotene." | 4.89 | Thyroid dysfunction as an unintended side effect of anticancer drugs. ( Appetecchia, M; Baldelli, R; Barnabei, A; Corsello, SM; Paragliola, R; Torino, F, 2013) |
| "This review aimed to (1) evaluate the effectiveness of thalidomide, and (2) identify and assess adverse effects from thalidomide for cancer cachexia." | 4.88 | Thalidomide for managing cancer cachexia. ( Cantwell, M; Cardwell, CR; Donnelly, M; Mills, M; Murray, LJ; Reid, J, 2012) |
| "With the increase in the number of reports and trials on the use of thalidomide as a part of the treatment of different medical conditions, particularly multiple myeloma (MM), it was observed that this drug might be associated with an increase in the risk of venous thromboembolic (VTE) events." | 4.84 | Thalidomide and thrombosis. A meta-analysis. ( El Accaoui, RN; Shamseddeen, WA; Taher, AT, 2007) |
| "The evolution of thalidomide as an effective treatment in several neoplasms has led to the search for compounds with increased antiangiogenic and anti-tumor effects, but decreased side-effects." | 4.84 | Thalidomide analogues as anticancer drugs. ( Aragon-Ching, JB; Figg, WD; Gardner, ER; Li, H, 2007) |
| "Acitretin, apremilast, and methotrexate are safe and effective modalities for ICI-mediated psoriasis." | 4.02 | Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. ( Annunziata, MC; Apalla, Z; Carrera, C; Fabbrocini, G; Fattore, D; Giacchero, D; Lallas, A; Lallas, K; Lazaridou, E; Nikolaou, V; Ortiz-Brugués, A; Patri, A; Peris, K; Riganti, J; Rigopoulos, D; Romano, MC; Rossi, E; Sibaud, V; Sollena, P; Stratigos, AJ; Voudouri, D, 2021) |
| " Although thalidomide and its derivatives, lenalidomide and pomalidomide, are widely used as an essential component in the treatment of selected hematologic neoplasms including multiple myeloma, the precise mechanisms by which these agents exert anti-tumor effects have yet to be clarified." | 3.80 | [Immunomodulatory drugs (IMiDs)]. ( Ichinohe, T; Oshima, K, 2014) |
| "Deep venous thrombosis (DVT) is a common complication of thalidomide treatment." | 3.73 | Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis. ( Baumann, MA; Ikhlaque, N; Kathula, S; Seshadri, V, 2006) |
| "Thalidomide is being increasingly used after stem cell transplantation as immunosuppression for patients with chronic graft-versus-host disease, as well as for antiangiogenesis effects in patients with multiple myeloma, brain tumors, leukemia, or other malignancies." | 3.71 | Thalidomide in chronic graft-versus-host disease after stem cell transplantation: effects on quality of life. ( Mehta, P; Miller, S; Rodrigue, J; Sharda, S, 2002) |
| "In the past three decades of cancer research, angiogenesis has been at its peak, where an anti-angiogenic agent inhibiting vascular endothelial growth factor acts as a promising substance to treat cancer." | 2.82 | Studying molecular signaling in major angiogenic diseases. ( Nathan, J; Palanivel, G; Shameera, R, 2022) |
| "Lenalidomide was given orally on days 1-14, oxaliplatin and leucovorin were given intravenously on day 1, and 5-fluorouracil was given as a continuous infusion on days 1-2." | 2.82 | Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. ( Falchook, G; Fu, S; Hong, DS; Naing, A; Piha-Paul, S; Said, R; Tsimberidou, AM; Wheler, JJ; Ye, Y, 2016) |
| "Twenty-six patients with advanced cancer (14 men/12 women), median age of 56 years (range 38-70 years), and a median number of two prior therapies (range 0-12) were enrolled." | 2.80 | Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. ( Abdelrahim, M; Bilen, MA; Erguvan-Dogan, B; Falchook, GS; Fu, S; Hong, DS; Kurzrock, R; Naing, A; Ng, CS; Tsimberidou, AM; Wheler, JJ, 2015) |
| "Lenalidomide and sorafenib was well tolerated and associated with disease stabilization for ≥6 months in patients with melanoma, adenoid cystic carcinoma, and ovarian adenocarcinoma." | 2.79 | Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. ( Bedikian, AY; Falchook, G; Fu, S; Ganesan, P; Hong, DS; Janku, F; Kies, M; Kurzrock, R; Laday, S; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Wolff, RA, 2014) |
| "Preclinical models show that an antiangiogenic regimen at low-dose daily (metronomic) dosing may be effective against chemotherapy-resistant tumors." | 2.79 | A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. ( Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA, 2014) |
| "The management of cancer-related anorexia/cachexia syndrome (CACS) is a great challenge in clinical practice." | 2.77 | Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide. ( Cao, YZ; Li, X; Peng, LM; Shi, YM; Wen, HS; Yang, F; Zhang, CC, 2012) |
| "Pomalidomide was well tolerated and the recommended phase II dosing schedules are 7 mg daily given for 21 days followed by a 7-day rest or pomalidomide 4 mg given on an uninterrupted daily schedule." | 2.77 | Phase I trial of pomalidomide given for patients with advanced solid tumors. ( Bokar, J; Cooney, MM; Dowlati, A; Dreicer, R; Gibbons, J; Krishnamurthi, S; Ness, A; Nock, C; Remick, SC; Rodal, MB, 2012) |
| "Cohorts of children with solid tumors received lenalidomide once daily for 21 days, every 28 days at dose levels of 15 to 70 mg/m(2)/dose." | 2.76 | Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. ( Adamson, PC; Ayello, J; Berg, SL; Blaney, SM; Cairo, MS; Chen, N; Ingle, AM; Lau, H; Russell, H, 2011) |
| " Pharmacokinetic data when irinotecan was administered as a single agent in each arm were compared to data when the two study agents were co-administered using paired t tests." | 2.76 | The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients. ( Cohen, EE; House, LK; Innocenti, F; Janisch, L; Karrison, T; Ramírez, J; Ratain, MJ; Wu, K, 2011) |
| " The recommended phase II dosing is docetaxel 75 mg/m(2) on day 1, lenalidomide 25 mg on days 1-14, and pegfilgrastim 6 mg on day 2, given every 3 weeks." | 2.74 | Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. ( Bako, J; Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Horvath, N; Krishnamurthi, S; Nock, C; Remick, SC; Sanborn, SL, 2009) |
| "Lenalidomide was well tolerated up to a 35-mg/d intermittent dosing schedule at doses higher than previously indicated for hematologic malignancies." | 2.74 | Phase I study of oral lenalidomide in patients with refractory metastatic cancer. ( Aragon-Ching, JB; Arlen, PM; Dahut, WL; Figg, WD; Gulley, JL; Tohnya, TM; Ventiz, J; Woo, S; Wright, JJ, 2009) |
| "Lenalidomide is an immunomodulatory derivative of thalidomide with significantly greater in vitro activity and a different toxicity profile." | 2.73 | Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors. ( Borden, E; Bukowski, R; Cline-Burkhardt, M; Davis, M; Dowlati, A; Dreicer, R; Kalmadi, S; Mekhail, T; O'Keefe, S; Pelley, RJ, 2007) |
| "Thalidomide 100 mg was kept stable for all cohorts." | 2.73 | A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. ( Khan, MI; Kloecker, GH; Laber, DA; Salvador, C; Schonard, C; Taft, BS, 2007) |
| " The recommended phase II dosing schedule is thalidomide 100 mg twice daily with docetaxel 25 mg/m(2)/week." | 2.73 | Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles. ( Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Krishnamurthi, S; Ness, A; Nock, C; Remick, SC; Sanborn, SL, 2008) |
| "Drug discovery in the scope of cancer therapy has been focused on conventional agents that nonselectively induce DNA damage or selectively inhibit the activity of key oncogenic molecules without affecting their protein levels." | 2.72 | Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer. ( Barghout, SH, 2021) |
| "Anorexia is the common symptom of malnutrition in cancer patients." | 2.72 | Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment. ( Hariyanto, TI; Kurniawan, A, 2021) |
| "Thalidomide is an anti-angiogenic agent currently used to treat patients with malignant cachexia or multiple myeloma." | 2.72 | Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. ( Daines, CA; Dalgleish, AG; Knight, RD; O'Byrne, KJ; Sharma, RA; Steward, WP, 2006) |
| " In all, 87% of adverse effects were classified as grade 1 or grade 2 according to Common Toxicity Criteria and there were no serious adverse events attributable to CC-5013 treatment." | 2.71 | Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. ( Bartlett, JB; Clarke, IA; Dalgleish, AG; Dredge, K; Kristeleit, H; Michael, A; Muller, GW; Nicholson, S; Pandha, H; Polychronis, A; Stirling, DI; Zeldis, J, 2004) |
| "Thalidomide was administered daily by mouth." | 2.71 | Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. ( Aleksic, A; Berg, SL; Blaney, SM; Bomgaars, LR; Chintagumpala, M; Klenke, RA; Kuttesch, JF, 2004) |
| " However, soon after their introduction into clinical practice, chemotherapy-induced peripheral neurotoxicity (CIPN) emerged as their main non-hematological and among dose-limiting adverse events." | 2.61 | Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment. ( Alberti, P; Argyriou, AA; Islam, B; Kolb, N; Lustberg, M; Staff, NP, 2019) |
| "Studies have recruited heterogeneous cancer patient populations in late disease stages, and many had issues with accrual and attrition." | 2.61 | Anti-cytokines in the treatment of cancer cachexia. ( Prado, BL; Qian, Y, 2019) |
| "In cases of malignancy that are refractive to treatment, other therapies have been found to be effective for paraneoplastic itch, including selective serotonin reuptake inhibitors, mirtazapine, gabapentin, thalidomide, opioids, aprepitant, and histone deacetylase inhibitors." | 2.53 | Paraneoplastic Itch Management. ( Rowe, B; Yosipovitch, G, 2016) |
| "Hence, thalidomide is effective in cancer treatment due to the interaction between immune cells and tumor vasculature." | 2.53 | Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review). ( Li, S; Lv, M; Shen, Y; Wang, F; Wang, X; Yang, J; Zhang, X, 2016) |
| "Thalidomide has immunomodulatory and anti-tumor necrosis factor-α effects as well as antiangiogenic properties, making it useful for a broad spectrum of inflammatory disorders." | 2.52 | Review of thalidomide use in the pediatric population. ( Antaya, RJ; Kim, C; Yang, CS, 2015) |
| "Thalidomide was synthesised and launched several decades ago as a drug against respiratory infections and was administered to pregnant women for relief of morning sickness." | 2.52 | Therapeutic Potential of Thalidomide and Its Analogues in the Treatment of Cancer. ( Sherbet, GV, 2015) |
| "Thalidomide is a synthetic glutamic acid derivative first introduced in 1956 in Germany as an over the counter medications." | 2.50 | [Current therapeutic indications of thalidomide and lenalidomide]. ( Cosiglio, FJ; Ordi-Ros, J, 2014) |
| "In patients with advanced cancer, AIDS and end-stage organ diseases, symptoms of cachexia syndrome include decrease in appetite, weight loss, decreased performance status, and an increase in the systemic inflammatory response." | 2.50 | Immunomodulatory agents for the treatment of cachexia. ( Bhargava, R; Chasen, M; Hirschman, S, 2014) |
| "Importantly, the IMiDs possess anti-cancer activity with selectivity for molecularly defined subgroups of hematological malignancies, specifically mature B-cell neoplasms and myelodysplasia with deletion of chromosome 5q." | 2.49 | Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. ( Hsu, AK; Johnstone, RW; Shortt, J, 2013) |
| "Lenalidomide is a thalidomide analogue with immunomodulatory and anti-angiogenic properties that include altering cytokine production, activating T cells, and augmenting natural killer cell function." | 2.48 | Lenalidomide in solid tumors. ( Segler, A; Tsimberidou, AM, 2012) |
| "In the Vienna Cancer and Thrombosis Study (CATS) the score was expanded by adding two biomarkers, and the prediction of VTE was considerably improved." | 2.48 | Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. ( Ay, C; Pabinger, I; Thaler, J, 2012) |
| "However, novel anticancer strategies (including tyrosine kinase inhibitors and monoclonal antibodies, as well as antiangiogenetic treatments) are becoming relevant in veterinary medicine, too." | 2.47 | [New concepts in human oncology: is it possible to use them in veterinary medicine as well?]. ( Buchholz, J; Kaser-Hotz, B; Marconato, L; Ruess-Melzer, K, 2011) |
| "Thalidomide has a broad spectrum of anti-cancer activity." | 2.47 | Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications. ( Bodera, P; Stankiewicz, W, 2011) |
| "Primary hypothyroidism is the most common side effect, although thyrotoxicosis and effects on thyroid-stimulating hormone secretion and thyroid hormone metabolism have also been described." | 2.47 | Thyroid dysfunction from antineoplastic agents. ( Hamnvik, OP; Larsen, PR; Marqusee, E, 2011) |
| "Targeted therapies against cancer have become more and more important." | 2.46 | Compounds in clinical Phase III and beyond. ( Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C, 2010) |
| "Thalidomide is a drug with bad reputation from the 1960's as it appeared to be teratogenic by causing foetal anomalies." | 2.46 | [Thalidomide in oncological and hematological diseases]. ( Anttila, P; Kivivuori, SM, 2010) |
| "Lenalidomide is a functional and structural analogue of thalidomide with a relatively benign toxicity profile and pleiotropic anti-tumor activity, exhibiting anti-angiogenic and immunomodulatory effects." | 2.46 | Lenalidomide: a synthetic compound with an evolving role in cancer management. ( Grivas, PD; Saloura, V, 2010) |
| "Lenalidomide is an IMiD® immunomodulatory compound, incorporating structural modification of the drug thalidomide, which is active against a wide variety of autoimmune Th-2-dependent disorders, including erythema nodosum of leprosy, leishmaniasis, as well as severe ulcerative disorders such as Behcet's syndrome." | 2.46 | The potential of immunomodulatory drugs in the treatment of solid tumors. ( Dalgleish, A; Galustian, C, 2010) |
| "Lenalidomide is a novel analog of thalidomide with both immunomodulatory and antiangiogenic properties that are more potent than those same properties in the parent compound." | 2.44 | Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors. ( Dreicer, R, 2007) |
| "Lenalidomide is an immunomodulatory drug that was developed by modification of the first-generation immunomodulatory drug thalidomide in a drug discovery program." | 2.44 | Lenalidomide: the emerging role of a novel targeted agent in malignancies. ( Baz, R; Kalmadi, S; Mahindra, A, 2007) |
| " The most common Grade 3/4 adverse events experienced on thalidomide monotherapy were venous thrombosis (3." | 2.44 | Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature. ( Claflin, JE; Crean, S; Lahn, M; Linz, H; Noel, JK; Ranganathan, G, 2008) |
| "Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies." | 2.43 | Thalidomide and immunomodulatory drugs in the treatment of cancer. ( Bamias, A; Dimopoulos, MA, 2005) |
| "Thalidomide and IMiDs inhibit the cytokines tumor necrosis factor-alpha (TNF-alpha), interleukins (IL) 1beta, 6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF)." | 2.43 | Properties of thalidomide and its analogues: implications for anticancer therapy. ( Teo, SK, 2005) |
| " Their toxic profile is favorable, but during the drug development process some severe (sometimes lethal) toxicities have been observed, such as interstitial lung disease in patients treated with drugs targeting the epidermal growth factor receptor." | 2.43 | Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies). ( Awada, A; de Castro, G, 2006) |
| "Thalidomide is an immunomodulatory and antiangiogenic drug." | 2.42 | Thalidomide: from tragedy to promise. ( Cerny, T; Gillessen, S; Stolz, R; von Moos, R, 2003) |
| "Thalidomide has several targets and mechanisms of action: a hypnosedative effect, several immunomodulatory properties with an effect on the production of TNF-alpha and the balance between the different lymphocyte subsets and an antiangiogenic action." | 2.42 | Thalidomide: an old drug with new clinical applications. ( Laffitte, E; Revuz, J, 2004) |
| "Thalidomide was first produced in Germany in the 1950s." | 2.42 | [Thalidomide--new prospective therapy in oncology]. ( Pałgan, I; Pałgan, K, 2003) |
| "It is now well established that cancer growth is increased by angiogenic factors and that inhibition of angiogenesis decreases growth and metastatic potential." | 2.42 | [Anti angiogenesis]. ( Akaza, H; Blackledge, G; Carmichael, J; Isonishi, S; Kakeji, Y; Kurebayashi, J; Nakagawa, M; Nakamura, S; Ohashi, Y; Saijo, N; Sone, S; Tsuruo, T; Yamamoto, N, 2004) |
| "Thalidomide has already become part of standard therapy for the treatment of patients with relapsed and refractory multiple myeloma." | 2.42 | Thalidomid: current role in the treatment of non-plasma cell malignancies. ( Kumar, S; Rajkumar, SV; Witzig, TE, 2004) |
| "The activity of thalidomide in solid tumors is less prominent." | 2.42 | Thalidomide in cancer medicine. ( Bamias, A; Dimopoulos, MA; Eleutherakis-Papaiakovou, V, 2004) |
| "Thalidomide was developed in the 1950s as a sedative having only a low toxicity." | 2.42 | [New pharmacological availability of thalidomide based on experience in patients with multiple myeloma]. ( Murakami, H, 2004) |
| "Thalidomide is an effective agent to treat over 25 seemingly unrelated dermatological conditions that have an inflammatory or autoimmune basis." | 2.41 | Thalidomide in dermatology. ( Cooper, AJ; Wines, MP; Wines, NY, 2002) |
| "Thalidomide has recently shown considerable promise in the treatment of a number of conditions, such as leprosy and cancer." | 2.41 | Immunological effects of thalidomide and its chemical and functional analogs. ( Dalgleish, AG; Dredge, K; Marriott, JB, 2002) |
| "Thalidomide has been shown to block the activity of angiogenic substances like bFGF, VEGF and interleukin 6." | 2.41 | [Thalidomide. Clinical trials in cancer]. ( Politi, PM, 2000) |
| "Thalidomide was later found to very effectively suppress erythema nodosum leprosum (ENL)." | 2.41 | Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. ( Clark, TE; Edom, N; Larson, J; Lindsey, LJ, 2001) |
| "The thalidomide product is a racemic mixture of the L- and D-enantiomeric forms of a synthetic glutamic acid derivative that contains a phthalimide ring and a glutarimide ring." | 2.41 | Thalidomide: a remarkable comeback. ( Jacobson, JM, 2000) |
| "It has been investigated in a number of cancers including multiple myeloma, myelodysplastic syndromes, gliomas, Kaposi's sarcoma, renal cell carcinoma, advanced breast cancer, and colon cancer." | 2.41 | Thalidomide in cancer: potential uses and limitations. ( Mehta, J; Singhal, S, 2001) |
| "Thalidomide is a synthetic derivative of glutamic acid with sedative-hypnotic activity, which caused devastating teratogenic effects in the 1960s." | 2.41 | Thalidomide: an old sedative-hypnotic with anticancer activity? ( Alberti, AM; Capaccetti, B; Gasparini, G; Gattuso, D; Magnani, E; Morabito, A, 2001) |
| "Thalidomide has been used successfully in several other dermatologic disorders, including aphthous stomatitis, Behcet's syndrome, chronic cutaneous systemic lupus erythematosus, and graft-versus-host disease, the apparent shared characteristic of which is immune dysregulation." | 2.41 | Thalidomide: an antineoplastic agent. ( Amato, RJ, 2002) |
| "Its use in other tumors is under evaluation, with promise in renal cell carcinoma, prostate cancer, glioma, and Kaposi's sarcoma." | 2.41 | Thalidomide: emerging role in cancer medicine. ( Anderson, K; Hideshima, T; Richardson, P, 2002) |
| "Thalidomide has immunomodulatory and anti-angiogenic properties which may underlie its activity in cancer." | 2.41 | Thalidomide in cancer. ( Mehta, J; Singhal, S, 2002) |
| "Fifty per cent of all cancers occur in this age group and therefore there will be an expected rise in the total cancer burden." | 2.41 | Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. ( Lichtman, SM; Skirvin, JA, 2002) |
| "Palliative effects of thalidomide on cancer-related symptoms have also been observed, especially for geriatric patients with prostate cancer." | 2.41 | Thalidomide in cancer treatment: a potential role in the elderly? ( Kestell, P; Paxton, JW; Tingle, MD; Zhou, S, 2002) |
| "Thalidomide was first introduced to the market in Germany under the brand name of Contergan in 1956, as a non-barbiturate hypnotic, advocated to ensure a good nights sleep and to prevent morning sickness in pregnancy." | 2.41 | Mechanisms of action and potential therapeutic uses of thalidomide. ( Chabner, BA; Mujagić, H; Mujagić, Z, 2002) |
| "Apremilast is a novel oral agent that has recently been made available to dermatologists for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis." | 1.72 | Psoriatic patients with a history of cancer: A real-life experience with Apremilast treatment for 104 weeks. ( Bernardini, N; Maddalena, P; Mambrin, A; Marchesiello, A; Marraffa, F; Potenza, C; Proietti, I; Rossi, G; Skroza, N; Tolino, E; Volpe, S, 2022) |
| "The risk of developing a malignancy during treatment is an important consideration, and many studies have been conducted to determine the magnitude of this risk." | 1.51 | Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review ( Casseres, RG; Dumont, N; Gottlieb, AB; Her, MJ; Kahn, JS; Rosmarin, D, 2019) |
| "It is further posited that, in autism, the drugs act as "triggers" that disturb the pro-proliferative fetal milieu using the same, mainly epigenetic, mechanisms that they demonstrate in rapidly proliferating cancer cells." | 1.40 | Autism's cancer connection: the anti-proliferation hypothesis and why it may matter. ( Ward, CS, 2014) |
| "Nonobvious controlled polymeric pharmaceutical excipient, chitosan nanoparticles (CS-NPs) for lenalidomide encapsulation were geared up by the simple ionic cross linking method to get better bioavailability and to reduce under as well as overloading of hydrophobic and sparingly soluble drug lenalidomide towards cancer cells." | 1.40 | Studies on drug-polymer interaction, in vitro release and cytotoxicity from chitosan particles excipient. ( Gomathi, T; Govindarajan, C; Imran, PK; Kim, SK; Rose H R, MH; Sudha, PN; Venkatesan, J, 2014) |
| " We have investigated the role of artemisone (ATM), a novel derivative of artemisinin (ART) in a cancer setting both alone and in combination with established chemotherapeutic agents." | 1.37 | In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. ( Chan, WC; Dalgleish, AG; Gravett, AM; Haynes, RK; Krishna, S; Liu, WM; Wilson, NL, 2011) |
| "Activity against colorectal cancer cells was dependent on target antigen expression, but independent of KRAS status and FcγRIIIa genotype." | 1.37 | Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. ( Adams, M; Bartlett, JB; Lu, L; Parton, A; Schafer, P; Wu, L, 2011) |
| "Because of the anticancer, anti-angiogenic action and the wide range of applicability of the immunomodulatory drugs, including thalidomide analogs, lipid droplet-binding members of this family could represent a new class of agents by affecting ER-membrane integrity and perturbations of ER homeostasis." | 1.36 | Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells. ( Ayaydin, F; Baska, F; Fábián, G; Farkas, K; Fehér, LZ; Gyuris, M; Hegyi, P; Kanizsai, I; Kitajka, K; Madácsi, R; Magyary, I; Molnár, E; Ozsvári, B; Puskás, LG; Rásó, E; Vizler, C, 2010) |
| "In the treatment of tumors with thalidomide, a rationale for its use is that it inhibits angiogenesis." | 1.35 | Thalidomide and thalidomide transformed by pH-dependent hydrolysis or by liver enzyme treatment does Not impede the proliferation of endothelial cells. ( Sandoval, FG; Shannon, EJ, 2008) |
| "To investigate the anticancer property and possible mechanism of action of a novel sugar-substituted thalidomide derivative (STA-35) on HL-60 cells in vitro." | 1.35 | In vitro anticancer property of a novel thalidomide analogue through inhibition of NF-kappaB activation in HL-60 cells. ( Cui, JR; Li, M; Li, ZJ; Ma, YX; Sun, W; Xu, B; Yang, YP; Yi, WY, 2009) |
| "Hypothyroidism is an often underreported complication of cancer treatment." | 1.35 | Hypothyroidism: a growing complication of cancer treatment. ( Kurtin, SE, 2009) |
| "Thus thalidomide 400 mg was combined with celecoxib." | 1.34 | Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. ( Duan, W; Kleiber, B; Kuhn, J; Otterson, G; Panico, K; Phillips, G; Schaaf, L; Shah, M; Villalona-Calero, M; Wu, WH; Young, D, 2007) |
| "Thalidomide has gained renewed interest as a cancer therapeutic due to its potential antiangiogenic effects." | 1.33 | Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells. ( Dennis, PA; Figg, WD; Lepper, ER; Warfel, NA; Zhang, C, 2006) |
| "Goiter is relatively common in infants whose mothers were treated with propylthiouracil and other antithyroid drugs, yet they usually show normal thyroid function." | 1.25 | Human experiences related to adverse drug reactions to the fetus or neonate from some maternally administered drugs. ( Shirkey, HC, 1972) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (6.76) | 18.7374 |
| 1990's | 14 (6.31) | 18.2507 |
| 2000's | 110 (49.55) | 29.6817 |
| 2010's | 72 (32.43) | 24.3611 |
| 2020's | 11 (4.95) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 3 |
| Hitosugi, T | 1 |
| Zhang, L | 2 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 2 |
| Nuthakki, VK | 1 |
| Mudududdla, R | 1 |
| Bharate, SB | 1 |
| Joshi, TP | 1 |
| Duvic, M | 1 |
| Xu, G | 1 |
| Bernardini, N | 1 |
| Skroza, N | 1 |
| Marchesiello, A | 1 |
| Mambrin, A | 1 |
| Proietti, I | 1 |
| Tolino, E | 1 |
| Maddalena, P | 1 |
| Marraffa, F | 1 |
| Rossi, G | 1 |
| Volpe, S | 1 |
| Potenza, C | 1 |
| Nathan, J | 1 |
| Shameera, R | 1 |
| Palanivel, G | 1 |
| Chen, D | 1 |
| Lin, S | 1 |
| Zeng, Z | 1 |
| An, J | 1 |
| Yan, W | 1 |
| Gu, Z | 1 |
| Chen, L | 1 |
| He, B | 1 |
| Islam, B | 1 |
| Lustberg, M | 1 |
| Staff, NP | 1 |
| Kolb, N | 1 |
| Alberti, P | 1 |
| Argyriou, AA | 1 |
| Barghout, SH | 1 |
| Di Lernia, V | 1 |
| Casanova, DM | 1 |
| Ricci, C | 1 |
| Nikolaou, V | 1 |
| Sibaud, V | 1 |
| Fattore, D | 1 |
| Sollena, P | 1 |
| Ortiz-Brugués, A | 1 |
| Giacchero, D | 1 |
| Romano, MC | 1 |
| Riganti, J | 1 |
| Lallas, K | 1 |
| Peris, K | 2 |
| Voudouri, D | 1 |
| Lallas, A | 1 |
| Fabbrocini, G | 1 |
| Lazaridou, E | 1 |
| Carrera, C | 1 |
| Annunziata, MC | 1 |
| Rossi, E | 1 |
| Patri, A | 1 |
| Rigopoulos, D | 1 |
| Stratigos, AJ | 1 |
| Apalla, Z | 1 |
| Hariyanto, TI | 1 |
| Kurniawan, A | 1 |
| Liu, H | 1 |
| Ding, X | 1 |
| Liu, L | 1 |
| Mi, Q | 1 |
| Zhao, Q | 1 |
| Shao, Y | 1 |
| Ren, C | 1 |
| Kong, Y | 1 |
| Qiu, X | 1 |
| Elvassore, N | 1 |
| Yang, X | 1 |
| Yin, Q | 1 |
| Jiang, B | 1 |
| Pramanik, R | 1 |
| Agarwala, S | 1 |
| Gupta, YK | 1 |
| Thulkar, S | 1 |
| Vishnubhatla, S | 1 |
| Batra, A | 1 |
| Dhawan, D | 1 |
| Bakhshi, S | 1 |
| Crowley, J | 1 |
| Thaçi, D | 1 |
| Joly, P | 1 |
| Papp, KA | 1 |
| Goncalves, J | 1 |
| Day, RM | 1 |
| Chen, R | 1 |
| Shah, K | 1 |
| Ferrándiz, C | 1 |
| Cather, JC | 1 |
| Borhani, K | 1 |
| Bamdad, T | 1 |
| Hashempour, T | 1 |
| Qu, X | 1 |
| Teng, Y | 1 |
| Shi, J | 1 |
| Yu, P | 1 |
| Sun, T | 1 |
| Wang, J | 2 |
| Zhu, Z | 1 |
| Zhang, X | 2 |
| Zhao, M | 1 |
| Liu, J | 1 |
| Jin, B | 1 |
| Luo, Y | 1 |
| Teng, Z | 1 |
| Dong, Y | 1 |
| Wen, F | 1 |
| An, Y | 1 |
| Yuan, C | 1 |
| Chen, T | 1 |
| Chen, Y | 2 |
| Zhang, J | 2 |
| Wang, Z | 1 |
| Qu, J | 1 |
| Jin, F | 1 |
| Jin, X | 1 |
| Xie, X | 1 |
| Man, L | 1 |
| Fu, L | 1 |
| Liu, Y | 1 |
| Schmidt, C | 1 |
| Rotenstein, LS | 1 |
| Dusetzina, SB | 1 |
| Keating, NL | 1 |
| Łączkowski, KZ | 1 |
| Baranowska-Łączkowska, A | 1 |
| Prado, BL | 1 |
| Qian, Y | 1 |
| Kerckhove, N | 1 |
| Collin, A | 1 |
| Condé, S | 1 |
| Chaleteix, C | 1 |
| Pezet, D | 1 |
| Balayssac, D | 1 |
| Guastella, V | 1 |
| Fujiwara, Y | 1 |
| Sun, Y | 1 |
| Torphy, RJ | 1 |
| He, J | 1 |
| Yanaga, K | 1 |
| Edil, BH | 1 |
| Schulick, RD | 1 |
| Zhu, Y | 1 |
| Nemer, G | 1 |
| Khalil, A | 1 |
| Kahn, JS | 1 |
| Casseres, RG | 1 |
| Her, MJ | 1 |
| Dumont, N | 1 |
| Gottlieb, AB | 1 |
| Rosmarin, D | 1 |
| Wen, HS | 1 |
| Li, X | 1 |
| Cao, YZ | 1 |
| Zhang, CC | 1 |
| Yang, F | 1 |
| Shi, YM | 1 |
| Peng, LM | 1 |
| Ritchie, CS | 1 |
| Currow, DC | 1 |
| Abernethy, AP | 1 |
| Kutner, JS | 1 |
| Ali, I | 1 |
| Wani, WA | 1 |
| Haque, A | 1 |
| Saleem, K | 1 |
| Torino, F | 1 |
| Barnabei, A | 1 |
| Paragliola, R | 1 |
| Baldelli, R | 1 |
| Appetecchia, M | 1 |
| Corsello, SM | 1 |
| Ganesan, P | 2 |
| Piha-Paul, S | 3 |
| Naing, A | 4 |
| Falchook, G | 3 |
| Wheler, J | 2 |
| Fu, S | 3 |
| Hong, DS | 3 |
| Kurzrock, R | 2 |
| Janku, F | 2 |
| Laday, S | 2 |
| Bedikian, AY | 1 |
| Kies, M | 2 |
| Wolff, RA | 1 |
| Tsimberidou, AM | 5 |
| Ordi-Ros, J | 1 |
| Cosiglio, FJ | 1 |
| Wu, E | 2 |
| Zhou, S | 2 |
| Wang, F | 2 |
| Hsieh, TC | 1 |
| Wu, JM | 1 |
| Zinner, R | 1 |
| Robison, NJ | 1 |
| Campigotto, F | 1 |
| Chi, SN | 1 |
| Manley, PE | 1 |
| Turner, CD | 1 |
| Zimmerman, MA | 1 |
| Chordas, CA | 1 |
| Werger, AM | 1 |
| Allen, JC | 1 |
| Goldman, S | 1 |
| Rubin, JB | 1 |
| Isakoff, MS | 1 |
| Pan, WJ | 1 |
| Khatib, ZA | 1 |
| Comito, MA | 1 |
| Bendel, AE | 1 |
| Pietrantonio, JB | 1 |
| Kondrat, L | 1 |
| Hubbs, SM | 1 |
| Neuberg, DS | 1 |
| Kieran, MW | 1 |
| Ward, CS | 1 |
| Nicholson, B | 1 |
| Kumar, S | 3 |
| Agarwal, S | 1 |
| Eddins, MJ | 1 |
| Marblestone, JG | 1 |
| Wu, J | 1 |
| Kodrasov, MP | 1 |
| LaRocque, JP | 1 |
| Sterner, DE | 1 |
| Mattern, MR | 1 |
| Tefferi, A | 1 |
| Hudgens, S | 1 |
| Mesa, R | 1 |
| Gale, RP | 1 |
| Verstovsek, S | 1 |
| Passamonti, F | 1 |
| Cervantes, F | 1 |
| Rivera, C | 1 |
| Tencer, T | 1 |
| Khan, ZM | 1 |
| Gomathi, T | 1 |
| Govindarajan, C | 1 |
| Rose H R, MH | 1 |
| Sudha, PN | 1 |
| Imran, PK | 1 |
| Venkatesan, J | 1 |
| Kim, SK | 1 |
| Weisel, K | 1 |
| Kanz, L | 1 |
| Oshima, K | 1 |
| Ichinohe, T | 1 |
| Chasen, M | 1 |
| Bhargava, R | 1 |
| Hirschman, S | 1 |
| Bhogaraju, S | 1 |
| Dikic, I | 1 |
| Chu, SH | 1 |
| Lee, YJ | 1 |
| Lee, ES | 1 |
| Geng, Y | 1 |
| Wang, XS | 1 |
| Cleeland, CS | 1 |
| Yang, CS | 1 |
| Kim, C | 1 |
| Antaya, RJ | 1 |
| Bilen, MA | 1 |
| Falchook, GS | 1 |
| Ng, CS | 1 |
| Wheler, JJ | 2 |
| Abdelrahim, M | 1 |
| Erguvan-Dogan, B | 1 |
| Jacques, V | 1 |
| Czarnik, AW | 1 |
| Judge, TM | 1 |
| Van der Ploeg, LH | 1 |
| DeWitt, SH | 1 |
| Alonso, S | 1 |
| Su, M | 1 |
| Jones, JW | 1 |
| Ganguly, S | 1 |
| Kane, MA | 1 |
| Jones, RJ | 1 |
| Ghiaur, G | 1 |
| Sachdev, E | 1 |
| Gong, J | 1 |
| Rimel, B | 1 |
| Mita, M | 1 |
| Sherbet, GV | 1 |
| Said, R | 1 |
| Ye, Y | 1 |
| Rowe, B | 1 |
| Yosipovitch, G | 1 |
| Wang, X | 1 |
| Shen, Y | 1 |
| Li, S | 1 |
| Lv, M | 1 |
| Yang, J | 2 |
| Han, Z | 1 |
| Sun, X | 1 |
| Jiang, G | 1 |
| Du, X | 1 |
| Shannon, EJ | 1 |
| Sandoval, FG | 1 |
| Sanborn, SL | 2 |
| Gibbons, J | 3 |
| Krishnamurthi, S | 3 |
| Brell, JM | 2 |
| Dowlati, A | 4 |
| Bokar, JA | 2 |
| Nock, C | 3 |
| Horvath, N | 1 |
| Bako, J | 1 |
| Remick, SC | 3 |
| Cooney, MM | 3 |
| Bielenberg, DR | 1 |
| D'Amore, PA | 1 |
| Li, M | 1 |
| Sun, W | 1 |
| Yang, YP | 1 |
| Xu, B | 1 |
| Yi, WY | 1 |
| Ma, YX | 1 |
| Li, ZJ | 1 |
| Cui, JR | 1 |
| Galustian, C | 2 |
| Dalgleish, A | 2 |
| Dahut, WL | 1 |
| Aragon-Ching, JB | 2 |
| Woo, S | 1 |
| Tohnya, TM | 1 |
| Gulley, JL | 1 |
| Arlen, PM | 1 |
| Wright, JJ | 1 |
| Ventiz, J | 1 |
| Figg, WD | 5 |
| Zangari, M | 1 |
| Fink, LM | 1 |
| Elice, F | 2 |
| Zhan, F | 1 |
| Adcock, DM | 1 |
| Tricot, GJ | 1 |
| Holaday, JW | 1 |
| Berkowitz, BA | 1 |
| Kurtin, SE | 1 |
| Kessler, T | 1 |
| Bayer, M | 1 |
| Schwöppe, C | 1 |
| Liersch, R | 1 |
| Mesters, RM | 1 |
| Berdel, WE | 1 |
| Mantovani, G | 2 |
| Macciò, A | 1 |
| Madeddu, C | 1 |
| Serpe, R | 1 |
| Massa, E | 1 |
| Dessì, M | 1 |
| Panzone, F | 1 |
| Contu, P | 1 |
| de Rezende, LC | 1 |
| Silva, IV | 1 |
| Rangel, LB | 1 |
| Guimarães, MC | 1 |
| Gravett, AM | 1 |
| Liu, WM | 1 |
| Krishna, S | 1 |
| Chan, WC | 1 |
| Haynes, RK | 1 |
| Wilson, NL | 1 |
| Dalgleish, AG | 9 |
| Sirven, JI | 1 |
| Puskás, LG | 1 |
| Fehér, LZ | 1 |
| Vizler, C | 1 |
| Ayaydin, F | 1 |
| Rásó, E | 1 |
| Molnár, E | 1 |
| Magyary, I | 1 |
| Kanizsai, I | 1 |
| Gyuris, M | 1 |
| Madácsi, R | 1 |
| Fábián, G | 1 |
| Farkas, K | 1 |
| Hegyi, P | 1 |
| Baska, F | 1 |
| Ozsvári, B | 1 |
| Kitajka, K | 1 |
| Kivivuori, SM | 1 |
| Anttila, P | 1 |
| Kannappan, R | 1 |
| Yadav, VR | 1 |
| Aggarwal, BB | 1 |
| Wu, L | 1 |
| Parton, A | 1 |
| Lu, L | 1 |
| Adams, M | 1 |
| Schafer, P | 1 |
| Bartlett, JB | 3 |
| Saloura, V | 1 |
| Grivas, PD | 1 |
| Berg, SL | 2 |
| Cairo, MS | 1 |
| Russell, H | 1 |
| Ayello, J | 1 |
| Ingle, AM | 1 |
| Lau, H | 1 |
| Chen, N | 1 |
| Adamson, PC | 1 |
| Blaney, SM | 2 |
| Dasanu, CA | 1 |
| Schwartz, RA | 1 |
| Bauer, F | 1 |
| Davis, LK | 1 |
| Silver, JS | 1 |
| Reale, MA | 1 |
| Zeldis, JB | 1 |
| Knight, R | 1 |
| Hussein, M | 1 |
| Chopra, R | 1 |
| Muller, G | 4 |
| Davis, M | 2 |
| Lasheen, W | 1 |
| Walsh, D | 1 |
| Mahmoud, F | 1 |
| Bicanovsky, L | 1 |
| Lagman, R | 1 |
| Otto, S | 1 |
| Schreyer, C | 1 |
| Hafner, S | 1 |
| Mast, G | 1 |
| Ehrenfeld, M | 1 |
| Stürzenbaum, S | 1 |
| Pautke, C | 1 |
| Marconato, L | 1 |
| Ruess-Melzer, K | 1 |
| Buchholz, J | 1 |
| Kaser-Hotz, B | 1 |
| Ramírez, J | 1 |
| Wu, K | 1 |
| Janisch, L | 1 |
| Karrison, T | 1 |
| House, LK | 1 |
| Innocenti, F | 1 |
| Cohen, EE | 1 |
| Ratain, MJ | 1 |
| Bodera, P | 1 |
| Stankiewicz, W | 1 |
| Hamnvik, OP | 1 |
| Larsen, PR | 1 |
| Marqusee, E | 1 |
| Reid, J | 1 |
| Mills, M | 1 |
| Cantwell, M | 1 |
| Cardwell, CR | 1 |
| Murray, LJ | 1 |
| Donnelly, M | 1 |
| Segler, A | 1 |
| Pan, B | 1 |
| Lentzsch, S | 1 |
| Thaler, J | 1 |
| Ay, C | 1 |
| Pabinger, I | 1 |
| Bokar, J | 1 |
| Rodal, MB | 1 |
| Ness, A | 2 |
| Dreicer, R | 3 |
| Yennurajalingam, S | 1 |
| Willey, JS | 1 |
| Palmer, JL | 1 |
| Allo, J | 1 |
| Del Fabbro, E | 1 |
| Cohen, EN | 1 |
| Tin, S | 1 |
| Reuben, JM | 1 |
| Bruera, E | 3 |
| Shortt, J | 1 |
| Hsu, AK | 1 |
| Johnstone, RW | 1 |
| Ng, SS | 1 |
| Brown, M | 1 |
| Porter, SR | 1 |
| Jorge, J | 1 |
| Baidas, S | 1 |
| Tfayli, A | 1 |
| Bhargava, P | 1 |
| McBride, W | 1 |
| Friedrich, MJ | 1 |
| Marriott, JB | 5 |
| Clarke, IA | 2 |
| Dredge, K | 5 |
| Stirling, D | 2 |
| Kerbel, R | 1 |
| Folkman, J | 1 |
| Wines, NY | 1 |
| Cooper, AJ | 1 |
| Wines, MP | 1 |
| Miller, S | 1 |
| Sharda, S | 1 |
| Rodrigue, J | 1 |
| Mehta, P | 1 |
| Augustin, HG | 1 |
| von Moos, R | 1 |
| Stolz, R | 1 |
| Cerny, T | 1 |
| Gillessen, S | 1 |
| Streicher, HZ | 1 |
| Vereshchagina, LA | 1 |
| Schoenfeldt, M | 1 |
| Teo, SK | 2 |
| Muller, GW | 2 |
| Chen, RS | 1 |
| Thomas, SD | 1 |
| Stirling, DI | 2 |
| Chandula, RS | 1 |
| Elwood, JM | 1 |
| Gordon, JN | 1 |
| Goggin, PM | 1 |
| Dodd-Butera, T | 1 |
| Broderick, M | 1 |
| Fanelli, M | 1 |
| Sarmiento, R | 1 |
| Gattuso, D | 2 |
| Carillio, G | 1 |
| Capaccetti, B | 2 |
| Vacca, A | 1 |
| Roccaro, AM | 1 |
| Gasparini, G | 2 |
| Dudek, AZ | 1 |
| Pawlak, WZ | 1 |
| Kirstein, MN | 1 |
| Rodeghiero, F | 1 |
| Muehlbauer, PM | 1 |
| DIPAOLO, JA | 1 |
| BACH, A | 2 |
| BICHEL, J | 2 |
| HEJGAARD, JJ | 2 |
| MAUAD, MJ | 1 |
| ROE, FJ | 2 |
| MITCHLEY, BC | 2 |
| PAGNINI, G | 1 |
| DICARLO, R | 1 |
| SUGIURA, K | 1 |
| WUEST, HM | 1 |
| ALLEGRI, A | 1 |
| Laffitte, E | 1 |
| Revuz, J | 1 |
| Grover, JK | 1 |
| Vats, K | 1 |
| Michael, A | 1 |
| Nicholson, S | 1 |
| Kristeleit, H | 1 |
| Polychronis, A | 1 |
| Pandha, H | 1 |
| Zeldis, J | 1 |
| Pałgan, K | 1 |
| Pałgan, I | 1 |
| Akaza, H | 1 |
| Nakagawa, M | 1 |
| Tsuruo, T | 1 |
| Saijo, N | 1 |
| Sone, S | 1 |
| Yamamoto, N | 1 |
| Kakeji, Y | 1 |
| Nakamura, S | 1 |
| Kurebayashi, J | 1 |
| Isonishi, S | 1 |
| Ohashi, Y | 1 |
| Blackledge, G | 1 |
| Carmichael, J | 1 |
| Franks, ME | 1 |
| Macpherson, GR | 1 |
| Witzig, TE | 1 |
| Rajkumar, SV | 2 |
| Mitsiades, CS | 1 |
| Mitsiades, N | 1 |
| Eleutherakis-Papaiakovou, V | 2 |
| Bamias, A | 2 |
| Dimopoulos, MA | 3 |
| Sengupta, S | 1 |
| Kiziltepe, T | 1 |
| Sasisekharan, R | 1 |
| Cavaletti, G | 1 |
| Marmiroli, P | 1 |
| Murakami, H | 1 |
| Chintagumpala, M | 1 |
| Bomgaars, LR | 1 |
| Aleksic, A | 1 |
| Kuttesch, JF | 1 |
| Klenke, RA | 1 |
| Sleijfer, S | 1 |
| Kruit, WH | 1 |
| Stoter, G | 1 |
| Anand, G | 1 |
| Stroud, M | 1 |
| Vidal, M | 1 |
| Gasse, C | 1 |
| Garbay, C | 1 |
| Galons, H | 1 |
| Argilés, JM | 1 |
| Busquets, S | 1 |
| López-Soriano, FJ | 1 |
| Crane, E | 1 |
| List, A | 1 |
| Ikhlaque, N | 1 |
| Seshadri, V | 1 |
| Kathula, S | 1 |
| Baumann, MA | 1 |
| Villalona-Calero, M | 1 |
| Schaaf, L | 1 |
| Phillips, G | 1 |
| Otterson, G | 1 |
| Panico, K | 1 |
| Duan, W | 1 |
| Kleiber, B | 1 |
| Shah, M | 1 |
| Young, D | 1 |
| Wu, WH | 1 |
| Kuhn, J | 1 |
| de Castro, G | 1 |
| Awada, A | 1 |
| Warfel, NA | 1 |
| Lepper, ER | 1 |
| Zhang, C | 1 |
| Dennis, PA | 1 |
| Sharma, RA | 1 |
| Steward, WP | 1 |
| Daines, CA | 1 |
| Knight, RD | 1 |
| O'Byrne, KJ | 1 |
| Gilheeney, SW | 1 |
| Lyden, DC | 1 |
| Sgouros, S | 1 |
| Antunes, N | 1 |
| Gerald, W | 1 |
| Kramer, K | 1 |
| Lis, E | 1 |
| Meyers, P | 1 |
| Rosen, N | 1 |
| Thaler, HT | 1 |
| Trippett, T | 1 |
| Wexler, L | 1 |
| Dunkel, IJ | 1 |
| Curtiss, FR | 1 |
| Kalmadi, S | 2 |
| O'Keefe, S | 1 |
| Cline-Burkhardt, M | 1 |
| Pelley, RJ | 1 |
| Borden, E | 1 |
| Bukowski, R | 1 |
| Mekhail, T | 1 |
| Bennett, CL | 1 |
| Angelotta, C | 1 |
| Yarnold, PR | 1 |
| Evens, AM | 1 |
| Zonder, JA | 1 |
| Raisch, DW | 1 |
| Richardson, P | 2 |
| Baz, R | 1 |
| Mahindra, A | 1 |
| Miller, AA | 1 |
| Case, D | 1 |
| Harmon, M | 1 |
| Savage, P | 1 |
| Lesser, G | 1 |
| Hurd, D | 1 |
| Melin, SA | 1 |
| El Accaoui, RN | 1 |
| Shamseddeen, WA | 1 |
| Taher, AT | 1 |
| Laber, DA | 1 |
| Khan, MI | 1 |
| Kloecker, GH | 1 |
| Schonard, C | 1 |
| Taft, BS | 1 |
| Salvador, C | 1 |
| Davies, MJ | 1 |
| Li, H | 1 |
| Gardner, ER | 1 |
| Noel, JK | 1 |
| Crean, S | 1 |
| Claflin, JE | 1 |
| Ranganathan, G | 1 |
| Linz, H | 1 |
| Lahn, M | 1 |
| Ohyashiki, K | 1 |
| Zhu, D | 1 |
| Corral, LG | 1 |
| Fleming, YW | 1 |
| Stein, B | 1 |
| Paravar, T | 1 |
| Lee, DJ | 1 |
| Drouet, L | 1 |
| Bron, D | 1 |
| Ziegler, J | 1 |
| Phillips, PH | 1 |
| Pluda, JM | 1 |
| Cheson, BD | 1 |
| Ono, M | 2 |
| Kuwano, M | 2 |
| McCarty, MF | 1 |
| Wells, WA | 1 |
| Larkin, M | 1 |
| Yarchoan, R | 1 |
| Neumann, CM | 1 |
| Pituskin, E | 1 |
| Calder, K | 1 |
| Ball, G | 1 |
| Hanson, J | 1 |
| Calabrese, L | 1 |
| Fleischer, AB | 1 |
| Bay, JO | 1 |
| Tournilhac, O | 1 |
| Gutheil, J | 1 |
| Finucane, D | 1 |
| Deaner, PB | 1 |
| Thomas, DA | 1 |
| Kantarjian, HM | 1 |
| Neiger, BL | 1 |
| Hussein, MA | 1 |
| Adlard, JW | 1 |
| Politi, PM | 1 |
| Clark, TE | 1 |
| Edom, N | 1 |
| Larson, J | 1 |
| Lindsey, LJ | 1 |
| Jacobson, JM | 1 |
| Li, C | 1 |
| Leibovici, D | 1 |
| Lindner, A | 1 |
| Singhal, S | 2 |
| Mehta, J | 2 |
| Dolev, E | 1 |
| Tuinmann, G | 1 |
| Hegewisch-Becker, S | 1 |
| Hossfeld, DK | 1 |
| Onn, A | 1 |
| Tseng, JE | 1 |
| Herbst, RS | 1 |
| Morabito, A | 1 |
| Magnani, E | 1 |
| Alberti, AM | 1 |
| Zogakis, TG | 1 |
| Libutti, SK | 1 |
| Amato, RJ | 1 |
| Hidalgo, M | 1 |
| Pierson, AS | 1 |
| Holden, SN | 1 |
| Bergen, M | 1 |
| Eckhardt, SG | 1 |
| Hideshima, T | 1 |
| Anderson, K | 1 |
| Mathé, G | 1 |
| Skirvin, JA | 1 |
| Lichtman, SM | 1 |
| Kestell, P | 1 |
| Tingle, MD | 1 |
| Paxton, JW | 1 |
| Das, U | 1 |
| Mujagić, H | 1 |
| Chabner, BA | 1 |
| Mujagić, Z | 1 |
| Eisen, T | 1 |
| Napalkov, NP | 1 |
| Jarvik, ME | 1 |
| Fraumeni, JF | 1 |
| Shirkey, HC | 1 |
| Walters, MA | 1 |
| Kucera, J | 1 |
| Traldi, A | 1 |
| Vaccari, GL | 1 |
| Davoli, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a Double Blind Placebo Controlled Randomized Study[NCT01858571] | Phase 3 | 108 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Pilot Study to Evaluate the Efficacy and Safety of Apremilast in Patients of Chronic and Recurrent Erythema Nodosum Leprosum[NCT04822909] | Phase 4 | 10 participants (Actual) | Interventional | 2019-09-15 | Completed | ||
| Efficacy and Safety of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis[NCT06032858] | Phase 4 | 30 participants (Actual) | Interventional | 2022-03-06 | Completed | ||
| TACTIC: a Phase II Study of TAS-102 Monotherapy and Thalidomide Plus TAS-102 as Third-line Therapy and Beyond in Patients With Advanced Colorectal Carcinoma[NCT05266820] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-10-01 | Recruiting | ||
| Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer[NCT06017284] | Phase 3 | 100 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.[NCT03283488] | Phase 2 | 52 participants (Actual) | Interventional | 2019-03-26 | Completed | ||
| A Phase I Study of Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) in Patients With Advanced Cancers[NCT01183663] | Phase 1 | 180 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Prospective, Open Clinical Trial of Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding[NCT04680195] | Phase 2 | 62 participants (Anticipated) | Interventional | 2020-12-14 | Not yet recruiting | ||
| A Single-arm, Open, Prospective, Multi-center Study on Thalidomide Combined With First-line Chemotherapy and Monotherapy for Maintenance Treatment of Liver Metastases From Her2-negative Advanced Gastric Cancer[NCT05198856] | Phase 1/Phase 2 | 106 participants (Anticipated) | Interventional | 2022-03-10 | Not yet recruiting | ||
| Study of Thalidomide With First-line Chemotherapy and as Maintenance Treatment of Advanced Nonsquamous NSCLC With Epidermal Growth Factor Receptor Wild-Type or Unknown Mutation Status: A Multicenter, Randomized, Prospective Clinical Trial[NCT03062800] | Phase 2 | 232 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Anti-Angiogenic Chemotherapy: A Phase II Trial of the Oral 5-Drug Regimen (Thalidomide, Celecoxib, Fenofibrate, Etoposide and Cyclophosphamide) in Patients With Relapsed or Progressive Cancer[NCT00357500] | Phase 2 | 101 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial[NCT03003325] | Phase 2 | 127 participants (Actual) | Interventional | 2017-02-02 | Completed | ||
| A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523] | Phase 1 | 7 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.) | ||
| Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid™) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors[NCT00253344] | Phase 1 | 33 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| A Multidose Phase I Study of Oral CC5013, a Thalidomide Derivative, in Patients With Refractory Metastatic Cancer[NCT00031941] | Phase 1 | 0 participants | Interventional | 2002-04-30 | Completed | ||
| Phase I Study of CC-5013 (Lenalidomide NSC# 703813) in Pediatric Patients With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome[NCT00104962] | Phase 1 | 24 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| Multicenter, Randomized, Double-blind, Phase III Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) With Alteration in 5q- and Anemia Without the Need of Transfusion.[NCT01243476] | Phase 3 | 61 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273529] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-02-20 | Not yet recruiting | ||
| A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma[NCT00540007] | Phase 2 | 80 participants (Actual) | Interventional | 2007-09-06 | Completed | ||
| The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273581] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-02-18 | Not yet recruiting | ||
| Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Patients With Anorexia Associated With Advanced Lung Cancer: Randomized Double Blind Clinical Trial[NCT02802540] | Phase 2/Phase 3 | 78 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| A Single-Center, Open-Label, Between-Patient, Dose-Escalation Phase 1 Study of CDC-501 In Patients With Solid Tumors[NCT00046735] | Phase 1 | 24 participants (Actual) | Interventional | 2002-06-01 | Completed | ||
| Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions[NCT03113942] | Phase 2 | 26 participants (Actual) | Interventional | 2017-06-14 | Active, not recruiting | ||
| Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on Anti-Angiogenic Therapeutic Principles[NCT00049296] | Phase 1 | 26 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
27-week overall survival is the probability of patients remaining alive at 27-weeks from study entry estimated using with Kaplan-Meier methods. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
| Intervention | Probability (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | 0.61 |
27-week progression-free survival is the probability of patients remaining alive and progression-free at 27-weeks from study entry estimated using Kaplan-Meier methods. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed every 9 weeks on treatment and annually until death or initiation of new therapy, up to 27 weeks.
| Intervention | Probability (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | 0.31 |
Proportion of patients alive at 27 weeks without progressive disease (PD) and having tolerated therapy. As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Progressive disease was defined as >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease. For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: 27 weeks
| Intervention | proportion of patients (Number) |
|---|---|
| 5-drug Metronomic Antiangiogenic Regimen | .25 |
As appropriate for tumor type and location, gadolinium-enhanced MRI and other imaging modalites were used to assess response. Best response was regarded as best response at any single assessment. Response was defined as follows: complete resolution of all demonstrable tumor, complete response (CR); >/=50% decrease in the product of the 2 maximum perpendicular diameters relative to the baseline evaluation, partial response (PR); <50% decrease and <25% increase in product of diameters, stable disease (SD); and >/=25% increase in product of diameters, development of new areas of disease, or disease-attributable clinical deterioration or death, progressive disease (PD). For patients with leukemia PD was defined as >/=25% or >/=5,000 cells/mm3 increase in number of circulating cells, development of extramedullary disease, or other clinical evidence of progression. (NCT00357500)
Timeframe: Assessed at study entry, every 9 weeks on treatment and at treatment discontinuation, up to 27 weeks.
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Progressive Disease | Not Evaluable | |
| 5-drug Metronomic Antiangiogenic Regimen | 1 | 12 | 36 | 47 | 1 |
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 95 |
"Cytostatic overall response rate = CR + PR + SD greater than or equal to 6 months~Definitions per 2007 Cheson Lymphoma Response Criteria" (NCT00540007)
Timeframe: From 6 months through 3.5 years after study entry
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 15 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 18 |
-Duration of response: defined as the interval from the date of response (CR or PR) is documented to the date of progression, taking as reference the smallest measurements recorded since the treatment started (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.68 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 4.08 |
-Event-free survival (time to treatment failure) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death). (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.78 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 3.93 |
"Overall response rate = CR + PR~Definitions per 2007 Cheson Lymphoma Response Criteria" (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 21.0 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 28.6 |
Overall survival is defined as the time from entry onto the clinical trial until death as a result of any cause. (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 17.434 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 23.717 |
(NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.78 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 3.93 |
-Time to progression (TTP) is defined as the time from study entry until documented lymphoma progression or death as a result of lymphoma. (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.68 |
| Cohort 2 | 4.08 |
"Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0~The higher the grade the worse the adverse event was considered" (NCT00540007)
Timeframe: 30 days following the completion of treatment
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Leukopenia | Anemia | Lymphopenia | Thrombocytopenia | Fatigue | AST | ALT | Bilirubin | Sensory neuropathy | Dehydration | Infection without neutropenia | Infection with neutropenia | Edema | Dyspnea | Pleural effusion | Alkaline phosphatase | Abdominal pain | Low potassium | Low sodium | Low albumin | Low calcium | High calcium | Low phosphorus | Hearing loss | Thrombosis/embolism | Rash | Febrile neutropenia | Pneumonia | High potassium | Hyperuricemia | Confusion | Dizziness | Speech impairment | Chest pain | Extremity pain | Muscle pain | Secondary malignancy - MDS | |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 18 | 11 | 10 | 9 | 7 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cohort 2 | 20 | 13 | 4 | 10 | 8 | 2 | 1 | 1 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 |
112 reviews available for thalidomide and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Role of basic aminoalkyl chains in the lead optimization of Indoloquinoline alkaloids.
Topics: Alkaloids; Antimalarials; Antineoplastic Agents; Cell Proliferation; Indoles; Malaria; Molecular Str | 2022 |
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options.
Topics: Anti-Infective Agents; Antimalarials; Biological Therapy; Comorbidity; Dermatologic Agents; Diabetes | 2022 |
The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
Topics: Adaptor Proteins, Signal Transducing; Animals; Humans; Immunomodulating Agents; Ligands; Neoplasms; | 2022 |
Studying molecular signaling in major angiogenic diseases.
Topics: Angiogenesis Inhibitors; Bevacizumab; Cetuximab; Everolimus; Humans; Imatinib Mesylate; Neoplasms; N | 2022 |
Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment.
Topics: Antineoplastic Agents; Cohort Studies; Furans; Humans; Immunosuppressive Agents; Ketones; Neoplasms; | 2019 |
Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
Topics: Animals; Antineoplastic Agents; Drug Discovery; Fulvestrant; Humans; Molecular Targeted Therapy; Neo | 2021 |
Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment.
Topics: Anorexia; Appetite; Clinical Trials, Phase III as Topic; Eicosapentaenoic Acid; Growth Differentiati | 2021 |
Anti-cytokines in the treatment of cancer cachexia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cachexia; Cytokines; Etanercept; Forecast | 2019 |
[Chemotherapy-induced peripheral neuropathy: Symptomatology and epidemiology].
Topics: Antineoplastic Agents; Bortezomib; Humans; Immunosuppressive Agents; Neoplasms; Peripheral Nervous S | 2018 |
A Cautious Note on Thalidomide Usage in Cancer Treatment: Genetic Profiling of the TBX2 Sub-Family Gene Expression is Required.
Topics: Animals; Gene Expression; Humans; Neoplasms; T-Box Domain Proteins; Thalidomide | 2019 |
Thyroid dysfunction as an unintended side effect of anticancer drugs.
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2013 |
[Current therapeutic indications of thalidomide and lenalidomide].
Topics: Abnormalities, Drug-Induced; Anti-Inflammatory Agents; Antineoplastic Agents; Collagen Diseases; End | 2014 |
Thalidomide-a notorious sedative to a wonder anticancer drug.
Topics: Antineoplastic Agents; Cell Adhesion; Cytokines; Humans; Neoplasms; Neovascularization, Physiologic; | 2013 |
Thalidomide-a notorious sedative to a wonder anticancer drug.
Topics: Antineoplastic Agents; Cell Adhesion; Cytokines; Humans; Neoplasms; Neovascularization, Physiologic; | 2013 |
Thalidomide-a notorious sedative to a wonder anticancer drug.
Topics: Antineoplastic Agents; Cell Adhesion; Cytokines; Humans; Neoplasms; Neovascularization, Physiologic; | 2013 |
Thalidomide-a notorious sedative to a wonder anticancer drug.
Topics: Antineoplastic Agents; Cell Adhesion; Cytokines; Humans; Neoplasms; Neovascularization, Physiologic; | 2013 |
Thalidomide-a notorious sedative to a wonder anticancer drug.
Topics: Antineoplastic Agents; Cell Adhesion; Cytokines; Humans; Neoplasms; Neovascularization, Physiologic; | 2013 |
Thalidomide-a notorious sedative to a wonder anticancer drug.
Topics: Antineoplastic Agents; Cell Adhesion; Cytokines; Humans; Neoplasms; Neovascularization, Physiologic; | 2013 |
Thalidomide-a notorious sedative to a wonder anticancer drug.
Topics: Antineoplastic Agents; Cell Adhesion; Cytokines; Humans; Neoplasms; Neovascularization, Physiologic; | 2013 |
Thalidomide-a notorious sedative to a wonder anticancer drug.
Topics: Antineoplastic Agents; Cell Adhesion; Cytokines; Humans; Neoplasms; Neovascularization, Physiologic; | 2013 |
Thalidomide-a notorious sedative to a wonder anticancer drug.
Topics: Antineoplastic Agents; Cell Adhesion; Cytokines; Humans; Neoplasms; Neovascularization, Physiologic; | 2013 |
Discovery of Therapeutic Deubiquitylase Effector Molecules: Current Perspectives.
Topics: Animals; Catalytic Domain; Drug Design; Drug Screening Assays, Antitumor; Fluorescence Resonance Ene | 2014 |
Lenalidomide.
Topics: Animals; Antineoplastic Agents; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; N | 2014 |
Immunomodulatory agents for the treatment of cachexia.
Topics: Adipose Tissue; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Appetite; C-Reacti | 2014 |
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review.
Topics: Amitriptyline; Anticonvulsants; Antidepressive Agents; Antineoplastic Agents; Boronic Acids; Bortezo | 2015 |
Review of thalidomide use in the pediatric population.
Topics: Abnormalities, Drug-Induced; Adolescent; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Au | 2015 |
Therapeutic Potential of Thalidomide and Its Analogues in the Treatment of Cancer.
Topics: Angiogenesis Inhibitors; Animals; Female; Humans; Neoplasms; Pregnancy; Thalidomide | 2015 |
Paraneoplastic Itch Management.
Topics: Acantholysis; Acanthosis Nigricans; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Apre | 2016 |
Importance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (Review).
Topics: Animals; Cell Communication; Humans; Immunomodulation; Lymphocytes; Neoplasms; Neovascularization, P | 2016 |
Judah Folkman's contribution to the inhibition of angiogenesis.
Topics: Allergy and Immunology; Angiogenesis Inhibitors; Animals; Cyclohexanes; History, 20th Century; Histo | 2008 |
Lenalidomide: a novel anticancer drug with multiple modalities.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Humans; Lenalidomide; Molecu | 2009 |
Thrombotic events in patients with cancer receiving antiangiogenesis agents.
Topics: Angiogenesis Inhibitors; Anticoagulants; Female; Follow-Up Studies; Humans; Immunologic Factors; Inc | 2009 |
Compounds in clinical Phase III and beyond.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostati | 2010 |
Regulatory T cell as a target for cancer therapy.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Humans; Immunotherapy; L | 2010 |
[Thalidomide in oncological and hematological diseases].
Topics: Angiogenesis Inhibitors; Female; Hematologic Diseases; Humans; Multiple Myeloma; Neoplasms; Pregnanc | 2010 |
Lenalidomide: a synthetic compound with an evolving role in cancer management.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematologic Di | 2010 |
The potential of immunomodulatory drugs in the treatment of solid tumors.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunologic Factors; Immunomodulation; Lena | 2010 |
A review of the history, properties, and use of the immunomodulatory compound lenalidomide.
Topics: Drug Discovery; History, 20th Century; History, 21st Century; Humans; Immunologic Factors; Lenalidom | 2011 |
[New concepts in human oncology: is it possible to use them in veterinary medicine as well?].
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antimetabolite | 2011 |
Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Evaluation, Preclinical; Humans; Immu | 2011 |
Thyroid dysfunction from antineoplastic agents.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antica | 2011 |
Drug profiles.
Topics: Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal; Drug Approval; Drug Costs; Humans; Ipili | 2012 |
Thalidomide for managing cancer cachexia.
Topics: Adult; Anti-Inflammatory Agents; Cachexia; Humans; Immunosuppressive Agents; Neoplasms; Randomized C | 2012 |
Lenalidomide in solid tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clin | 2012 |
The application and biology of immunomodulatory drugs (IMiDs) in cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid | 2012 |
Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials.
Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Lenalidomide; Models, Biological; Multiple Myelo | 2012 |
Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Topics: Animals; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Epigenesis, Genetic | 2013 |
Thalidomide, an antiangiogenic agent with clinical activity in cancer.
Topics: Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, P | 2002 |
Thalidomide: a role in oral oncology?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Mouth Neoplasms; N | 2002 |
Thalidomide: an old drug with new clinical applications.
Topics: Autoimmune Diseases; HIV Infections; Humans; Immunosuppressive Agents; Neoplasms; Skin Diseases; Tha | 2002 |
Clinical translation of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Cell Movement; Clinical Trials as Topic; Drug Resistance, Neoplasm; Genes, | 2002 |
Thalidomide in dermatology.
Topics: Dermatologic Agents; Humans; Neoplasms; Skin Diseases; Thalidomide | 2002 |
[Angiogenesis research--quo vadis?].
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2003 |
Thalidomide: from tragedy to promise.
Topics: Angiogenesis Inhibitors; Hematologic Neoplasms; History, 20th Century; Humans; Immunosuppressive Age | 2003 |
Thalidomide and its derivatives: emerging from the wilderness.
Topics: Adjuvants, Immunologic; Cachexia; Crohn Disease; Graft vs Host Disease; Hematologic Neoplasms; Human | 2003 |
Immunological effects of thalidomide and its chemical and functional analogs.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Antiviral Agents; HIV Infections; Humans; Immune Sy | 2002 |
Thalidomide: a new anticancer drug?
Topics: Animals; Antineoplastic Agents; Cachexia; Hematologic Neoplasms; Humans; Neoplasms; Thalidomide | 2003 |
Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Humans; Neoplasm | 2003 |
Molecular targets in the inhibition of angiogenesis.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Angiopoietins; Animals; Cell Division; Clinical Trials | 2003 |
Anti-angiogenesis in cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Clinical Trials as Topic; Endothelial Growth Factor | 2003 |
Thalidomide: an old drug with new clinical applications.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Clinical Trials as Topic; Humans; Hypnotics and Sed | 2004 |
Thalidomide: from teratogen to anti-angiogenic.
Topics: Angiogenesis Inhibitors; Humans; Male; Multiple Myeloma; Neoplasms; Prostatic Neoplasms; Thalidomide | 2001 |
[Thalidomide--new prospective therapy in oncology].
Topics: Analgesics; Angiogenesis Inhibitors; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Huma | 2003 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
The evolution of thalidomide and its IMiD derivatives as anticancer agents.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials as Topic; | 2004 |
[Anti angiogenesis].
Topics: Angiogenesis Inhibitors; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Cyclooxyg | 2004 |
Thalidomide.
Topics: Clinical Trials as Topic; Gastrointestinal Diseases; HIV Infections; Humans; Neoplasms; Rheumatic Di | 2004 |
Thalidomid: current role in the treatment of non-plasma cell malignancies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Teratog | 2004 |
CC-5013 (Celgene).
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cli | 2004 |
Thalidomide in cancer medicine.
Topics: Angiogenesis Inhibitors; Cachexia; Clinical Trials as Topic; Graft vs Host Disease; Humans; Multiple | 2004 |
Adverse effects of thalidomide administration in patients with neoplastic diseases.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Agents; Clinical Trials, Phase II | 2004 |
Chemotherapy-induced peripheral neurotoxicity.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Epothilones; Humans; Neoplasms; Neuroprote | 2004 |
[New pharmacological availability of thalidomide based on experience in patients with multiple myeloma].
Topics: Animals; Blood Vessels; Clinical Trials, Phase II as Topic; Ectromelia; Erythema Nodosum; Female; Hu | 2004 |
Thalidomide in solid tumours: the resurrection of an old drug.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasms; Thalidom | 2004 |
Thalidomide and immunomodulatory drugs in the treatment of cancer.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Neoplasms; Nervous System Diseases; Thalidomide | 2005 |
Thalidomide and cancer cachexia: old problem, new hope?
Topics: Angiogenesis Inhibitors; Cachexia; Humans; Neoplasms; Pancreatic Neoplasms; Thalidomide | 2005 |
The pivotal role of cytokines in muscle wasting during cancer.
Topics: Animals; Anorexia; Antibodies; Cachexia; Cytokines; Humans; Models, Biological; Muscle, Skeletal; Mu | 2005 |
Properties of thalidomide and its analogues: implications for anticancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Adhesion Molecules; Clinical Trials, | 2005 |
Lenalidomide: an immunomodulatory drug.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunologic Factors; Lenalidomide; | 2005 |
Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies).
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Design; Farnesyltranstransferase; Humans; Imm | 2006 |
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
Topics: Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms; Thalidomide; Thromboembolism | 2006 |
Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors.
Topics: Angiogenesis Inhibitors; Humans; Immunologic Factors; Lenalidomide; Neoplasms; Thalidomide | 2007 |
Lenalidomide: the emerging role of a novel targeted agent in malignancies.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Lenalidomide; Multiple Myeloma; M | 2007 |
Thalidomide and thrombosis. A meta-analysis.
Topics: Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Agents, Hormonal; Dexamethasone; Humans; Mul | 2007 |
Management of novel therapeutics' side effects: a nurse-centric model.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Monitoring; Humans; Lenalidomide; Models, Nur | 2007 |
Thalidomide analogues as anticancer drugs.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Mole | 2007 |
Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; p38 Mitogen-Activated Prot | 2008 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematini | 2008 |
Thalidomide: mechanisms of action.
Topics: Angiogenesis Inhibitors; Erythema Nodosum; Humans; Immune System; Immunity, Active; Immunity, Innate | 2008 |
[Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers].
Topics: Angiogenesis Inhibitors; Humans; Neoplasms; Risk Factors; Thalidomide; Thromboembolism; Venous Throm | 2008 |
Graft-versus-host disease.
Topics: Acute Disease; Adolescent; Adult; Bone Marrow Transplantation; Child; Chronic Disease; Clinical Tria | 1994 |
[Development of anti tumor agents targeting angiogenesis].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclohexanes; Drug Screening Assays, Antitumor; Enz | 1997 |
Pharmacological treatment of cachexia: any progress?
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Antiemetics; Antioxidants; Appetite Stimulants; C | 1998 |
[Neovascularization and tumor development].
Topics: Angiostatins; Antibiotics, Antineoplastic; Antineoplastic Agents; Collagen; Cyclohexanes; Endostatin | 1998 |
Therapy for Kaposi's sarcoma: recent advances and experimental approaches.
Topics: Administration, Oral; Alitretinoin; Anthracyclines; Antineoplastic Agents; Cyclohexanes; Humans; Imm | 1999 |
Thalidomide as an emerging immunotherapeutic agent.
Topics: Abnormalities, Drug-Induced; Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Anti-Inflam | 1999 |
Thalidomide: current and potential clinical applications.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Arthritis, Rheumatoid; Behcet Syndrome; Dermatologic Agent | 2000 |
Current role of thalidomide in cancer treatment.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials as Topic; Graft vs Host Disease; Hum | 2000 |
Research on thalidomide in solid tumors, hematologic malignancies, and supportive care.
Topics: Antioxidants; DNA Damage; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Neoplasms; Neovascul | 2000 |
Thalidomide in the treatment of cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms | 2000 |
[Thalidomide. Clinical trials in cancer].
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Multiple Myeloma; | 2000 |
Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
Topics: Angiogenesis Inhibitors; Anti-HIV Agents; Drug Labeling; Erythema Nodosum; Female; Hallucinations; H | 2001 |
Thalidomide: a remarkable comeback.
Topics: Angiogenesis Inhibitors; Animals; HIV Infections; Humans; Immunosuppressive Agents; Neoplasms; Thali | 2000 |
[Thalidomide and cancer--revival of a drug].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Survival; Humans; Neoplasms; Teratogen | 2001 |
Thalidomide in cancer: potential uses and limitations.
Topics: Animals; Antineoplastic Agents; Humans; Immunosuppressive Agents; Neoplasms; Thalidomide | 2001 |
[The thalidomide story and its lessons].
Topics: Abnormalities, Drug-Induced; Anti-HIV Agents; Antineoplastic Agents; Female; Germany; History, 20th | 2001 |
Current status of thalidomide in the treatment of cancer.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Hematologic Neoplasms; Humans; Multiple Myeloma; | 2001 |
[New indications for thalidomide?].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiogenesis Inhibitors; Animals; Anti-HIV Agents; A | 2001 |
Thalidomide: an old sedative-hypnotic with anticancer activity?
Topics: Animals; Antineoplastic Agents; Hematologic Neoplasms; Humans; Neoplasms; Teratogens; Thalidomide | 2001 |
Immunotherapeutic and antitumour potential of thalidomide analogues.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Antineoplastic Agents; Clinical Trials as Topic; Cyclic Nucleot | 2001 |
General aspects of anti-angiogenesis and cancer therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies; Clinical Trials as Topic; Collagen; Cyclohexanes; Endo | 2001 |
Thalidomide: an antineoplastic agent.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; HIV Infections; H | 2002 |
Therapeutic angiogenesis inhibitors in the treatment of cancer.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Collagen | 2001 |
Thalidomide: emerging role in cancer medicine.
Topics: Adjuvants, Immunologic; Angiogenesis Inhibitors; Animals; Clinical Trials as Topic; Humans; Multiple | 2002 |
Thalidomide in cancer.
Topics: Angiogenesis Inhibitors; Bradycardia; Exanthema; Humans; Interleukin-2; Interleukin-6; Neoplasms; Pe | 2002 |
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary | 2002 |
Thalidomide in cancer treatment: a potential role in the elderly?
Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Human | 2002 |
A radical approach to cancer.
Topics: 2-Methoxyestradiol; Anaerobiosis; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antioxida | 2002 |
Mechanisms of action and potential therapeutic uses of thalidomide.
Topics: Clinical Trials as Topic; Humans; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasms; Risk Asses | 2002 |
[Transplacental carcinogenesis].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Abnormalities, Drug-Induced; Adenocarcinoma; Animals; Carcinogens; | 1977 |
31 trials available for thalidomide and Benign Neoplasms
| Article | Year |
|---|---|
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy P | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Depression; Diarrhea; Femal | 2017 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2017 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2017 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2017 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2017 |
Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide.
Topics: Aged; Appetite Stimulants; Body Weight; Cachexia; Drug Therapy, Combination; Fatigue; Female; Hand S | 2012 |
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free S | 2014 |
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2013 |
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxi | 2014 |
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Topics: Anemia; Bayes Theorem; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Myeloproliferativ | 2014 |
Phase I trial of valproic acid and lenalidomide in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; L | 2015 |
Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Re | 2016 |
Thalidomide for Control Delayed Vomiting in Cancer Patients Receiving Chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; China; Double-Blind Method; Drug-Related Side Effec | 2016 |
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Resp | 2009 |
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Resp | 2009 |
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Resp | 2009 |
Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Resp | 2009 |
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag | 2009 |
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag | 2009 |
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag | 2009 |
Phase I study of oral lenalidomide in patients with refractory metastatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lenalidomide; Male; Middle Ag | 2009 |
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia.
Topics: Appetite Stimulants; Cachexia; Carnitine; Eicosapentaenoic Acid; Female; Humans; Interleukin-6; Male | 2010 |
Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
Topics: Aged; Body Composition; Cachexia; Carnitine; Contraceptives, Oral, Hormonal; Eicosapentaenoic Acid; | 2010 |
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans | 2011 |
A Phase II dose titration study of thalidomide for cancer-associated anorexia.
Topics: Aged; Anorexia; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Female; Humans; | 2012 |
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cross-Over Studies; Drug Interactions; Humans; Irin | 2011 |
Phase I trial of pomalidomide given for patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, D | 2012 |
The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Cachexia; Double-Blind Method; Female; Humans; Immunosuppr | 2012 |
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive | 2002 |
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive | 2002 |
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive | 2002 |
Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibodies, Monoclonal; Antigens, CD; CD3 Complex; CD4-Positive | 2002 |
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cytokines; Female; Fibroblast G | 2004 |
Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Ch | 2004 |
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans | 2006 |
A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Child; C | 2007 |
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; | 2007 |
Phase I study of lenalidomide in solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relations | 2007 |
Phase I study of lenalidomide in solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relations | 2007 |
Phase I study of lenalidomide in solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relations | 2007 |
Phase I study of lenalidomide in solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relations | 2007 |
A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2007 |
Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease Progre | 2008 |
Thalidomide in patients with cachexia due to terminal cancer: preliminary report.
Topics: Aged; Appetite; Cachexia; Female; Humans; Hypnotics and Sedatives; Male; Neoplasm Metastasis; Neopla | 1999 |
Thalidomide therapy in refractory solid tumour patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Human | 2000 |
79 other studies available for thalidomide and Benign Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Psoriatic patients with a history of cancer: A real-life experience with Apremilast treatment for 104 weeks.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Psoriatic; Chronic Disease; Humans; Neoplasms; P | 2022 |
Serendipitous discovery of Class I HDAC inhibitors from rational design of molecular glue degraders targeting HDAC.
Topics: Histone Deacetylase Inhibitors; Humans; Neoplasms; Thalidomide | 2024 |
Apremilast in patients with history of malignancy: a real-life, single-center experience.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Neoplasms; Psoriasis; Thalidomide | 2021 |
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
Topics: Acitretin; Aged; Biological Products; Dermatologic Agents; Drug Therapy, Combination; Europe; Female | 2021 |
Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Topics: Animals; Cell Proliferation; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Half-Life; Humans; K5 | 2021 |
Lenalidomide acts as an adjuvant for HCV DNA vaccine.
Topics: Adjuvants, Immunologic; Animals; Cell Line, Tumor; Female; Humans; Killer Cells, Natural; Lenalidomi | 2017 |
The struggle to do no harm in clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Tri | 2017 |
Out-of-Pocket Spending Not Associated with Oral Oncolytic Survival Benefit.
Topics: Adult; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Prescriptions; Female; Health E | 2018 |
Recent studies on the thalidomide and its derivatives.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Humans; Multiple Myeloma; Neoplasms; Neovascular | 2018 |
Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cytotoxicity, Immunologic; Gene Exp | 2018 |
Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Female; Humans; Male; Middle Aged; Neo | 2019 |
Multisite studies offer a solution to recruitment challenges in palliative care studies.
Topics: Anorexia; Cachexia; Female; Humans; Immunosuppressive Agents; Male; Neoplasms; Thalidomide | 2013 |
Glutamic acid and its derivatives: candidates for rational design of anticancer drugs.
Topics: Antineoplastic Agents; Drug Carriers; Drug Design; Glutamic Acid; Humans; Neoplasms; Thalidomide | 2013 |
discovering new anticancer activities from old drugs.
Topics: Antineoplastic Agents; Databases, Factual; Humans; Neoplasms; Pharmaceutical Preparations; Thalidomi | 2013 |
Autism's cancer connection: the anti-proliferation hypothesis and why it may matter.
Topics: Antineoplastic Agents; Autistic Disorder; Epigenetic Repression; Gene Expression Regulation, Neoplas | 2014 |
Studies on drug-polymer interaction, in vitro release and cytotoxicity from chitosan particles excipient.
Topics: Angiogenesis Inhibitors; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Cross-Linking Reagents; | 2014 |
[Immunomodulatory drugs (IMiDs)].
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Neoplasms; Thali | 2014 |
A peek into the atomic details of thalidomide's clinical effects.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Female; Humans; Models, Molecu | 2014 |
Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Female; H | 2015 |
Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P- | 2015 |
Adnectin-targeted inhibitors: rationale and results.
Topics: Adenine; Angiogenesis Inhibitors; Antineoplastic Agents; Bortezomib; Clinical Trials as Topic; Drug | 2015 |
Thalidomide and thalidomide transformed by pH-dependent hydrolysis or by liver enzyme treatment does Not impede the proliferation of endothelial cells.
Topics: Angiogenesis Inhibitors; Cell Proliferation; Cells, Cultured; Endothelial Cells; Humans; Hydrogen-Io | 2008 |
In vitro anticancer property of a novel thalidomide analogue through inhibition of NF-kappaB activation in HL-60 cells.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; G | 2009 |
Antiangiogenic drugs: insights into drug development from endostatin, avastin and thalidomide.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevaciz | 2009 |
Hypothyroidism: a growing complication of cancer treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Female; Humans; Hypothyroidism; Incidence; Iodide Per | 2009 |
In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents.
Topics: Antineoplastic Agents; Artemisinins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2011 |
New uses for older drugs: the tales of aspirin, thalidomide, and gabapentin.
Topics: Amines; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Aspirin; Cyclohexanecarboxylic Aci | 2010 |
Polyunsaturated fatty acids synergize with lipid droplet binding thalidomide analogs to induce oxidative stress in cancer cells.
Topics: Animals; Cell Line, Tumor; Drug Synergism; Embryo, Nonmammalian; Endoplasmic Reticulum; Fatty Acids, | 2010 |
γ-Tocotrienol but not γ-tocopherol blocks STAT3 cell signaling pathway through induction of protein-tyrosine phosphatase SHP-1 and sensitizes tumor cells to chemotherapeutic agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Boronic Acids; Bor | 2010 |
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.
Topics: Antibodies, Blocking; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent | 2011 |
Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; D | 2011 |
Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Thalidomide and cancer.
Topics: Adult; Animals; Humans; Immunosuppressive Agents; Neoplasms; Rabbits; Thalidomide; Time Factors; Uni | 2002 |
Despite checkered past, thalidomide and its analogues show potential.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunosuppressive A | 2002 |
Thalidomide in chronic graft-versus-host disease after stem cell transplantation: effects on quality of life.
Topics: Case-Control Studies; Chronic Disease; Graft vs Host Disease; Humans; Immunosuppressive Agents; Neop | 2002 |
Bibliography. Current world literature. Therapeutic modalities.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dip | 2002 |
Clinical trials referral resource. Current clinical trials of thalidomide.
Topics: Angiogenesis Inhibitors; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Tria | 2003 |
Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline.
Topics: Adjuvants, Immunologic; Antineoplastic Agents; Humans; In Vitro Techniques; Neoplasms; Sodium Chlori | 2003 |
Thalidomide and cancer?
Topics: Humans; Immunosuppressive Agents; Neoplasms; Thalidomide | 2003 |
Thalidomide makes a comeback.
Topics: Abnormalities, Drug-Induced; Angiogenesis Inhibitors; Ectromelia; Erythema Nodosum; Female; Humans; | 2003 |
Thalidomide and thrombosis.
Topics: Humans; Incidence; Neoplasms; Thalidomide; Thrombophilia; Thrombosis | 2003 |
Effect of thalidomide on a variety of transplantable tumors.
Topics: Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Thalidomide | 1963 |
STUDIES ON THE POSSIBLE ANTI-NEOPLASTIC EFFECT OF THALIDOMIDE.
Topics: Adenocarcinoma; Antineoplastic Agents; Leukemia; Leukemia, Experimental; Mice; Neoplasms; Neoplasms, | 1963 |
[CLINICAL IMPROVEMENTS OBTAINED IN ADVANCED CANCER PATIENTS WITH TREATMENT WITH THALIDOMIDE ASSOCIATED WITH HORMONES].
Topics: Adrenal Cortex Hormones; Anabolic Agents; Antineoplastic Agents; Hormones; Neoplasms; Steroids; Test | 1963 |
THALIDOMIDE AND NEOPLASIA.
Topics: Carcinogens; Carcinoma, Hepatocellular; Liver Neoplasms; Lymphoma; Mice; Neoplasms; Neoplasms, Exper | 1963 |
[TREATMENT OF EXPERIMENTAL TUMORS WITH THALIDOMIDE].
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Mice; Multiple Myeloma; Neoplasms; Neoplasms, Experime | 1963 |
EFFECT OF THALIDOMIDE ON TRANSPLANTABLE MOUSE, RAT, AND HAMSTER TUMORS.
Topics: Animals; Cricetinae; Infections; Injections; Injections, Intraperitoneal; Leukemia; Leukemia, Experi | 1964 |
[CONFIRMED INEFFECTIVENESS OF THALIDOMIDE IN THE THERAPY OF TUMORS].
Topics: Geriatrics; Humans; Neoplasms; Thalidomide | 1964 |
[STUDIES IN REGARD TO THE POSSIBLE ANTI-NEOPLASTIC EFFECT OF THALIDOMIDE].
Topics: Antineoplastic Agents; Leukemia; Leukemia, Experimental; Mice; Neoplasms; Neoplasms, Experimental; P | 1963 |
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; D | 2004 |
How drug's rebirth as treatment for cancer fueled price rises.
Topics: Drug Industry; HIV Wasting Syndrome; Humans; Multiple Myeloma; Neoplasms; Thalidomide | 2004 |
The new cancer blockers.
Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humaniz | 2004 |
[Search for new anti-angiogenic agents with structural analogy with thalidomide].
Topics: Angiogenesis Inhibitors; Cell Line; Cell Proliferation; Endothelial Cells; Humans; Neoplasms; Phosph | 2005 |
Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Cohort Studies; Female; Hem | 2006 |
Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Celecoxib; Chemother | 2007 |
Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.
Topics: Animals; Butadienes; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose- | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecit | 2006 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Ant | 2008 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Ant | 2008 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Ant | 2008 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Ant | 2008 |
Angiogenesis research enjoys growth spurt in the 1990s.
Topics: Antineoplastic Agents; Cyclohexanes; Drugs, Investigational; Endothelial Growth Factors; Humans; Int | 1996 |
Clinical trials referral resource. Clinical trials using thalidomide.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunosuppressive Agents; Neoplasms; Thalid | 1996 |
Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis.
Topics: Animals; Antineoplastic Agents; Callithrix; Fish Oils; Gene Expression; Humans; Hyperplasia; Inflamm | 1997 |
A cautious comeback for thalidomide.
Topics: Abnormalities, Drug-Induced; Antineoplastic Agents; Graft vs Host Disease; HIV Wasting Syndrome; Hum | 1998 |
Starving cancer into submission. EntreMed, Inc.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antineoplastic Agents; Humans; Mice; Neoplasms; Neov | 1998 |
Thwarting the dwindling progression of cachexia.
Topics: Cachexia; HIV Infections; Humans; Neoplasms; Thalidomide | 1998 |
The problem with thalidomide's new incarnation.
Topics: Acquired Immunodeficiency Syndrome; Drug Approval; Humans; Leprosy; Neoplasms; Thalidomide; United S | 1998 |
[Importance of thalidomide in the treatment of cancer].
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Neoplasms; Neovas | 2000 |
The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report.
Topics: Adult; Aged; Female; Humans; Hyperhidrosis; Male; Middle Aged; Neoplasms; Quality of Life; Terminal | 2000 |
The re-emergence of thalidomide: results of a scientific conference.
Topics: Abnormalities, Drug-Induced; Adjuvants, Immunologic; Adolescent; Adult; Anti-HIV Agents; Anti-Inflam | 2000 |
Targeting of vasculature in cancer and other angiogenic diseases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antigens, CD; Arthritis, Rheumatoid; Diabetic Retin | 2001 |
Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy.
Topics: Angiogenesis Inhibitors; Animals; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhi | 2001 |
Thalidomide, a drug which may protect the organism against some aggressive effects of the immunologic system.
Topics: Acquired Immunodeficiency Syndrome; Erythema Nodosum; Graft vs Host Reaction; Humans; Immunosuppress | 2002 |
Thalidomide in solid malignancies.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; H | 2002 |
Necessary risks.
Topics: Animals; Antiemetics; Dogs; Dronabinol; Drug Industry; Drug-Related Side Effects and Adverse Reactio | 1979 |
The susceptibility of the fetus and child to chemical pollutants. Chemicals in human teratogenesis and transplacental carcinogenesis.
Topics: Abnormalities, Drug-Induced; Alkylating Agents; Amphetamine; Androgens; Anticonvulsants; Antithyroid | 1974 |
Human experiences related to adverse drug reactions to the fetus or neonate from some maternally administered drugs.
Topics: Abnormalities, Drug-Induced; Antineoplastic Agents; Antithyroid Agents; Contraceptives, Oral; Diethy | 1972 |
Tumour-incidence in progeny of thalidomide-treated mice.
Topics: Abnormalities, Drug-Induced; Animals; Animals, Newborn; Carcinoma, Hepatocellular; Female; Hodgkin D | 1967 |
Prospects and limitations of epidemiology in human teratology.
Topics: Abnormalities, Drug-Induced; Carcinogens; Chromosome Aberrations; Chromosome Disorders; Congenital A | 1973 |
[Use of the imide of N-phthalylglutamic acid (thalidomide) in the symptomatic therapy of vomiting of many patients with malignant neoplasms or caused by the administration of mechlorethamine HCl].
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Male; Mechlorethamine; Middle Aged; Neoplasms; Thali | 1965 |